Pharmaceutical Research

, Volume 30, Issue 2, pp 489–501

Identification of Novel Activators of Constitutive Androstane Receptor from FDA-Approved Drugs by Integrated Computational and Biological Approaches

  • Caitlin Lynch
  • Yongmei Pan
  • Linhao Li
  • Stephen S. Ferguson
  • Menghang Xia
  • Peter W. Swaan
  • Hongbing Wang
Research Paper

DOI: 10.1007/s11095-012-0895-1

Cite this article as:
Lynch, C., Pan, Y., Li, L. et al. Pharm Res (2013) 30: 489. doi:10.1007/s11095-012-0895-1

Abstract

Purpose

The constitutive androstane receptor (CAR, NR1I3) is a xenobiotic sensor governing the transcription of numerous hepatic genes associated with drug metabolism and clearance. Recent evidence suggests that CAR also modulates energy homeostasis and cancer development. Thus, identification of novel human (h) CAR activators is of both clinical importance and scientific interest.

Methods

Docking and ligand-based structure-activity models were used for virtual screening of a database containing over 2000 FDA-approved drugs. Identified lead compounds were evaluated in cell-based reporter assays to determine hCAR activation. Potential activators were further tested in human primary hepatocytes (HPHs) for the expression of the prototypical hCAR target gene CYP2B6.

Results

Nineteen lead compounds with optimal modeling parameters were selected for biological evaluation. Seven of the 19 leads exhibited moderate to potent activation of hCAR. Five out of the seven compounds translocated hCAR from the cytoplasm to the nucleus of HPHs in a concentration-dependent manner. These compounds also induce the expression of CYP2B6 in HPHs with rank-order of efficacies closely resembling that of hCAR activation.

Conclusion

These results indicate that our strategically integrated approaches are effective in the identification of novel hCAR modulators, which may function as valuable research tools or potential therapeutic molecules.

KEY WORDS

CARCYP2B6hepatocytesinductionpharmacophore

Abbreviations

Ad/EYFP-hCAR

adenovirus expressing enhanced yellow fluorescent protein-tagged human CAR

AMI

amiodarone

CAL

carvedilol

CAR

constitutive androstane receptor

CITCO

6-(4-chlorophenyl) imidazo[2,1-b][1,3]-thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime

CYP

cytochrome P450

DMSO

dimethyl sulfoxide

GAPDH

glyceraldehyde-3-phosphate dehydrogenase

HPH

human primary hepatocytes

LBD

ligand-binding domain

NEF

nefazodone

NIC

nicardipine

OCT

octicizer

PB

phenobarbital

PXR

pregnane X receptor

RT-PCR

reverse transcription-polymerase chain reaction

TEL

telmisartan

TOL

tolnaftate

Supplementary material

11095_2012_895_MOESM1_ESM.docx (20 kb)
ESM 1(DOCX 19 kb)
11095_2012_895_Fig7_ESM.jpg (116 kb)
Figure S1

Chemical structures of training compounds. Seventeen known human CAR ligands extracted from literature were used as training compounds to generate the common features of pharmacophore model in this study. The chemical structures of these compounds were drawn using ChemDraw Ultra 10. (JPEG 115 kb)

11095_2012_895_MOESM2_ESM.tif (5.2 mb)
High Resolution Image(TIFF 5344 kb)
11095_2012_895_Fig8_ESM.jpg (152 kb)
Figure S2

Chemical structures of tested lead compounds. Nineteen lead compounds with optimal pharmacophore parameters from virtual screening of the FDA-approved drug data base were selected for biological assessment of CAR activation. The chemical structures of these compounds were drawn using ChemDraw Ultra 10. (JPEG 151 kb)

11095_2012_895_MOESM3_ESM.tif (6.4 mb)
High Resolution Image(TIFF 6602 kb)

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Caitlin Lynch
    • 1
  • Yongmei Pan
    • 1
  • Linhao Li
    • 1
  • Stephen S. Ferguson
    • 2
  • Menghang Xia
    • 3
  • Peter W. Swaan
    • 1
  • Hongbing Wang
    • 1
  1. 1.Department of Pharmaceutical SciencesUniversity of Maryland School of PharmacyBaltimoreUSA
  2. 2.Life Technologies CorporationsDurhamUSA
  3. 3.NIH Chemical Genomics CenterNational Institutes of HealthBethesdaUSA